3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
7
Unknown
2
Terminated
2
Recruiting
2
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Head & Neck
1
Gastrointestinal
1
Conditions
Breast Neoplasms
704
Carcinoma, Non-Small-Cell Lung
470
Prostatic Neoplasms
420
Neoplasms
380
Multiple Myeloma
264
Colorectal Neoplasms
261
Lung Neoplasms
247
Neoplasm Metastasis
229
Melanoma
215
Ovarian Neoplasms
191
Leukemia, Myeloid, Acute
189
Pancreatic Neoplasms
182
Squamous Cell Carcinoma of Head and Neck
163
Recurrence
147
Carcinoma, Renal Cell
145
Lymphoma
142
Glioblastoma
138
Lymphoma, Non-Hodgkin
135
Stomach Neoplasms
128
Triple Negative Breast Neoplasms
127
Brain Neoplasms
124
Carcinoma, Hepatocellular
123
Leukemia, Lymphocytic, Chronic, B-Cell
122
Uterine Cervical Neoplasms
117
Head and Neck Neoplasms
117
Precursor Cell Lymphoblastic Leukemia-Lymphoma
115
Urinary Bladder Neoplasms
113
Lymphoma, Large B-Cell, Diffuse
105
Sarcoma
102
Lymphoma, Follicular
100
Interventions
pembrolizumab
1
Cetuximab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Interventional
×
Noonan Syndrome
×
Clear all
NCT04670679
2026-03-25
FLAGSHP-1
Erasca, Inc.
Phase 1
Active not recruiting
90 enrolled